Kelsey Goodwin
Stock Analyst at Guggenheim
(1.16)
# 3,532
Out of 4,761 analysts
15
Total ratings
40%
Success rate
-5.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kelsey Goodwin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GNLX Genelux | Initiates: Buy | $8 | $4.81 | +66.32% | 1 | Oct 29, 2024 | |
| NUVL Nuvalent | Maintains: Buy | $99 → $105 | $79.49 | +32.09% | 2 | Sep 16, 2024 | |
| URGN UroGen Pharma | Initiates: Buy | $40 | $10.08 | +296.83% | 1 | Aug 22, 2024 | |
| MGNX MacroGenics | Downgrades: Neutral | n/a | $2.76 | - | 1 | Jul 31, 2024 | |
| TSVT 2seventy bio | Downgrades: Neutral | n/a | $2.61 | - | 4 | Sep 13, 2023 | |
| ACLX Arcellx | Maintains: Buy | n/a | $63.75 | - | 3 | Jun 20, 2023 | |
| LEGN Legend Biotech | Initiates: Neutral | n/a | $39.70 | - | 1 | Oct 31, 2022 | |
| IOVA Iovance Biotherapeutics | Initiates: Neutral | n/a | $5.78 | - | 1 | Oct 31, 2022 | |
| IPSC Century Therapeutics | Initiates: Buy | $15 | $0.73 | +1,954.51% | 1 | Oct 31, 2022 |
Genelux
Oct 29, 2024
Initiates: Buy
Price Target: $8
Current: $4.81
Upside: +66.32%
Nuvalent
Sep 16, 2024
Maintains: Buy
Price Target: $99 → $105
Current: $79.49
Upside: +32.09%
UroGen Pharma
Aug 22, 2024
Initiates: Buy
Price Target: $40
Current: $10.08
Upside: +296.83%
MacroGenics
Jul 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.76
Upside: -
2seventy bio
Sep 13, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.61
Upside: -
Arcellx
Jun 20, 2023
Maintains: Buy
Price Target: n/a
Current: $63.75
Upside: -
Legend Biotech
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $39.70
Upside: -
Iovance Biotherapeutics
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $5.78
Upside: -
Century Therapeutics
Oct 31, 2022
Initiates: Buy
Price Target: $15
Current: $0.73
Upside: +1,954.51%